Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Dimethyl fumarate protection against collagen II degradation.
A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray.
Teriflunomide
Potassium channel KIR4.1 as an immune target in multiple sclerosis.
Vitamin D3 attenuates oxidative stress and cognitive deficits in a model of toxic demyelination.
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview.
New TECFIDERA® (dimethyl fumarate) data show sustained efficacy and long-term safety in a broad range of multiple sclerosis patients
Developmental Origin of Oligodendrocyte Lineage Cells Determines Response to Demyelination and Susceptibility to Age-Associated Functional Decline.
Disease Modifying Therapies Modulate Cardiovascular Risk Factors in Multiple Sclerosis Patients.
Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.
Improvements in cognition, quality of life, and physical performance with clinical Pilates in multiple sclerosis: a randomized controlled trial.
Emerging Concepts on the Gut Microbiome and Multiple Sclerosis.
[Information processing speed and influential factors in multiple sclerosis].
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.
Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.
Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases.
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
Stride time variability as a marker for higher level of gait control in multiple sclerosis: its association with fear of falling.
Clobetasol promotes remyelination in a mouse model of neuromyelitis optica.
Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Alpha/beta interferon is a neuronal growth factor.
FGF-1 Triggers Pannexin-1 Hemichannel Opening in Spinal Astrocytes of Rodents and Promotes Inflammatory Responses in Acute Spinal Cord Slices.
Neuro-Immune Interactions at Barrier Surfaces.
LINGO-1, A TRANSMEMBRANE SIGNALING PROTEIN, INHIBITS OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION THROUGH INTERCELLULAR SELF-INTERACTIONS.
Detailed results from Biogen Idec and AbbVie's pivotal Phase 3 DECIDE study further define the efficacy and safety profile of ZINBRYTA™ (daclizumab high-yield process)
Pages
« first
‹ previous
…
76
77
78
79
80
81
82
83
84
…
next ›
last »